Abstract
In this paper we describe our strategy to improve the aqueous solubility of SCH 900229, a potent PS1-selective γ-secretase inhibitor for the treatment of Alzheimer's disease. Incorporation of ionizable amino groups into the side chain terminal generates water soluble β-aminosulfone analogues of SCH 900229 that maintain robust in vitro potency and in vivo efficacy.
Keywords:
Alzheimer’s disease; Aqueous solubility; β-Aminosulfone; γ-Secretase inhibitor.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / enzymology
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / metabolism
-
Animals
-
Benzopyrans / chemistry*
-
Benzopyrans / pharmacokinetics
-
Benzopyrans / pharmacology*
-
Dogs
-
Drug Design
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Haplorhini
-
Humans
-
Rats
-
Solubility
-
Sulfones / chemistry*
-
Sulfones / pharmacokinetics
-
Sulfones / pharmacology*
-
Water / chemistry
Substances
-
Benzopyrans
-
Enzyme Inhibitors
-
SCH 900229
-
Sulfones
-
Water
-
Amyloid Precursor Protein Secretases